364 related articles for article (PubMed ID: 12439032)
1. Intensified chemotherapy increases the survival rates in patients with stage 4 neuroblastoma with MYCN amplification.
Kaneko M; Tsuchida Y; Mugishima H; Ohnuma N; Yamamoto K; Kawa K; Iwafuchi M; Sawada T; Suita S
J Pediatr Hematol Oncol; 2002 Nov; 24(8):613-21. PubMed ID: 12439032
[TBL] [Abstract][Full Text] [Related]
2. Long-term survivors of advanced neuroblastoma with MYCN amplification: A report of 19 patients surviving disease-free for more than 66 months.
Kawa K; Ohnuma N; Kaneko M; Yamamoto K; Etoh T; Mugishima H; Ohhira M; Yokoyama J; Bessho F; Honna T; Yoshizawa J; Nakada K; Iwafuchi M; Nozaki T; Mimaya J; Sawada T; Nakamura T; Miyata H; Yamato K; Tsuchida Y
J Clin Oncol; 1999 Oct; 17(10):3216-20. PubMed ID: 10506621
[TBL] [Abstract][Full Text] [Related]
3. Commentary on Kaneko et al.: Intensified chemotherapy increases the survival rates in patients with stage 4 neuroblastoma with MYCN amplification.
Brodeur GM
J Pediatr Hematol Oncol; 2002 Nov; 24(8):608-9. PubMed ID: 12439030
[No Abstract] [Full Text] [Related]
4. Percentage tumor necrosis following chemotherapy in neuroblastoma correlates with MYCN status but not survival.
Bomken S; Davies B; Chong L; Cole M; Wood KM; McDermott M; Tweddle DA
Pediatr Hematol Oncol; 2011 Mar; 28(2):106-14. PubMed ID: 21214410
[TBL] [Abstract][Full Text] [Related]
5. Treatment combined with bone marrow transplantation for advanced neuroblastoma: an analysis of patients who were pretreated intensively with the protocol of the Study Group of Japan.
Ohnuma N; Takahashi H; Kaneko M; Uchino J; Takeda T; Iwafuchi M; Ohhira M; Nishihira H; Mugishima H; Yokoyama J
Med Pediatr Oncol; 1995 Mar; 24(3):181-7. PubMed ID: 7838040
[TBL] [Abstract][Full Text] [Related]
6. Prognostic significance of circulating tumor cells and bone marrow micrometastasis in advanced neuroblastoma.
Kuroda T; Morikawa N; Matsuoka K; Fujino A; Honna T; Nakagawa A; Kumagai M; Masaki H; Saeki M
J Pediatr Surg; 2008 Dec; 43(12):2182-5. PubMed ID: 19040931
[TBL] [Abstract][Full Text] [Related]
7. Implications of MYCN amplification in patients with stage 4 neuroblastoma who undergo intensive chemotherapy.
Suita S; Tajiri T; Kaneko M; Hirai M; Mugishima H; Sugimoto T; Tsuchida Y
J Pediatr Surg; 2007 Mar; 42(3):489-93. PubMed ID: 17336185
[TBL] [Abstract][Full Text] [Related]
8. Busulfan and melphalan versus carboplatin, etoposide, and melphalan as high-dose chemotherapy for high-risk neuroblastoma (HR-NBL1/SIOPEN): an international, randomised, multi-arm, open-label, phase 3 trial.
Ladenstein R; Pötschger U; Pearson ADJ; Brock P; Luksch R; Castel V; Yaniv I; Papadakis V; Laureys G; Malis J; Balwierz W; Ruud E; Kogner P; Schroeder H; de Lacerda AF; Beck-Popovic M; Bician P; Garami M; Trahair T; Canete A; Ambros PF; Holmes K; Gaze M; Schreier G; Garaventa A; Vassal G; Michon J; Valteau-Couanet D;
Lancet Oncol; 2017 Apr; 18(4):500-514. PubMed ID: 28259608
[TBL] [Abstract][Full Text] [Related]
9. Treatment results of advanced neuroblastoma with the first Japanese study group protocol. Study Group of Japan for Treatment of Advanced Neuroblastoma.
Kaneko M; Tsuchida Y; Uchino J; Takeda T; Iwafuchi M; Ohnuma N; Mugishima H; Yokoyama J; Nishihira H; Nakada K; Sasaki S; Sawada T; Kawa K; Nagahara N; Suita S; Sawaguchi S
J Pediatr Hematol Oncol; 1999; 21(3):190-7. PubMed ID: 10363851
[TBL] [Abstract][Full Text] [Related]
10. Stratification of treatment of stage 4 neuroblastoma patients based on N-myc amplification status. Study Group of Japan for Treatment of Advanced Neuroblastoma, Tokyo, Japan.
Kaneko M; Nishihira H; Mugishima H; Ohnuma N; Nakada K; Kawa K; Fukuzawa M; Suita S; Sera Y; Tsuchida Y
Med Pediatr Oncol; 1998 Jul; 31(1):1-7. PubMed ID: 9607422
[TBL] [Abstract][Full Text] [Related]
11. Improved survival for patients with advanced neuroblastoma after high-dose combined chemotherapy based in part on N-myc amplification.
Suita S; Tajiri T; Sera Y; Takamatsu H; Mizote H; Nagasaki A; Kurosaki N; Hara T; Okamura J; Miyazaki S; Sugimoto T; Kawakami K; Eguchi H; Tsuneyoshi M
J Pediatr Surg; 2000 Dec; 35(12):1737-41. PubMed ID: 11101726
[TBL] [Abstract][Full Text] [Related]
12. Poor survival for infants with MYCN-amplified metastatic neuroblastoma despite intensified treatment: the International Society of Paediatric Oncology European Neuroblastoma Experience.
Canete A; Gerrard M; Rubie H; Castel V; Di Cataldo A; Munzer C; Ladenstein R; Brichard B; Bermúdez JD; Couturier J; de Bernardi B; Pearson AJ; Michon J
J Clin Oncol; 2009 Mar; 27(7):1014-9. PubMed ID: 19171715
[TBL] [Abstract][Full Text] [Related]
13. N7: a novel multi-modality therapy of high risk neuroblastoma (NB) in children diagnosed over 1 year of age.
Cheung NK; Kushner BH; LaQuaglia M; Kramer K; Gollamudi S; Heller G; Gerald W; Yeh S; Finn R; Larson SM; Wuest D; Byrnes M; Dantis E; Mora J; Cheung IY; Rosenfield N; Abramson S; O'Reilly RJ
Med Pediatr Oncol; 2001 Jan; 36(1):227-30. PubMed ID: 11464891
[TBL] [Abstract][Full Text] [Related]
14. Outcomes of children with intermediate-risk neuroblastoma after treatment stratified by MYCN status and tumor cell ploidy.
Bagatell R; Rumcheva P; London WB; Cohn SL; Look AT; Brodeur GM; Frantz C; Joshi V; Thorner P; Rao PV; Castleberry R; Bowman LC
J Clin Oncol; 2005 Dec; 23(34):8819-27. PubMed ID: 16314642
[TBL] [Abstract][Full Text] [Related]
15. What is the benefit of aggressive chemotherapy for advanced neuroblastoma with N-myc amplification? A report from the Japanese Study Group for the Treatment of Advanced Neuroblastoma.
Suita S; Zaizen Y; Kaneko M; Uchino J; Takeda T; Iwafuchi M; Utsumi J; Takahashi H; Yokoyama J; Nishihira H
J Pediatr Surg; 1994 Jun; 29(6):746-50. PubMed ID: 8078011
[TBL] [Abstract][Full Text] [Related]
16. Outcome prediction by molecular detection of minimal residual disease in bone marrow for advanced neuroblastoma.
Horibe K; Fukuda M; Miyajima Y; Matsumoto K; Kondo M; Inaba J; Miyashita Y
Med Pediatr Oncol; 2001 Jan; 36(1):203-4. PubMed ID: 11464885
[TBL] [Abstract][Full Text] [Related]
17. Genetic staging of unresectable or metastatic neuroblastoma in infants: a Pediatric Oncology Group study.
Bowman LC; Castleberry RP; Cantor A; Joshi V; Cohn SL; Smith EI; Yu A; Brodeur GM; Hayes FA; Look AT
J Natl Cancer Inst; 1997 Mar; 89(5):373-80. PubMed ID: 9060959
[TBL] [Abstract][Full Text] [Related]
18. Localised and unresectable neuroblastoma in infants: excellent outcome with primary chemotherapy. Neuroblastoma Study Group, Société Française d'Oncologie Pédiatrique.
Rubie H; Plantaz D; Coze C; Michon J; Frappaz D; Baranzelli MC; Chastagner P; Peyroulet MC; Hartmann O;
Med Pediatr Oncol; 2001 Jan; 36(1):247-50. PubMed ID: 11464897
[TBL] [Abstract][Full Text] [Related]
19. Clinical outcomes and prognostic factors to predict treatment response in high risk neuroblastoma patients receiving topotecan and cyclophosphamide containing induction regimen: a prospective multicenter study.
Rujkijyanont P; Photia A; Traivaree C; Monsereenusorn C; Anurathapan U; Seksarn P; Sosothikul D; Techavichit P; Sanpakit K; Phuakpet K; Wiangnon S; Chotsampancharoen T; Chainansamit SO; Kanjanapongkul S; Meekaewkunchorn A; Hongeng S
BMC Cancer; 2019 Oct; 19(1):961. PubMed ID: 31619207
[TBL] [Abstract][Full Text] [Related]
20. [Evaluation of efficacy of treatment for 30 children with neuroblastoma].
Sun XF; Liu DG; Su YS; Lin TY; Chen XQ; He YJ
Ai Zheng; 2003 Dec; 22(12):1343-5. PubMed ID: 14693065
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
